Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 1 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar Smallcappy (< 20) Submitted: 8/14/2012 10:30:24 AM : Underperform Start Price: $2.64 PPHM Score: +52.76

It has been hyped up and due to fall.

Featured Broker Partners


Advertisement